ATE316787T1 - Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion - Google Patents

Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion

Info

Publication number
ATE316787T1
ATE316787T1 AT01988586T AT01988586T ATE316787T1 AT E316787 T1 ATE316787 T1 AT E316787T1 AT 01988586 T AT01988586 T AT 01988586T AT 01988586 T AT01988586 T AT 01988586T AT E316787 T1 ATE316787 T1 AT E316787T1
Authority
AT
Austria
Prior art keywords
fenofibrate
coenzyme
treatment
combination
endothelial disfunction
Prior art date
Application number
AT01988586T
Other languages
English (en)
Inventor
Gerald Watts
David Playford
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR1038A external-priority patent/AUPR103800A0/en
Priority claimed from AUPR3424A external-priority patent/AUPR342401A0/en
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Application granted granted Critical
Publication of ATE316787T1 publication Critical patent/ATE316787T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01988586T 2000-10-26 2001-10-23 Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion ATE316787T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR1038A AUPR103800A0 (en) 2000-10-26 2000-10-26 Compositions for the treatment of endothelial dysfunction
AUPR3424A AUPR342401A0 (en) 2001-02-28 2001-02-28 Compositions for the treatment of endothelial dysfunction

Publications (1)

Publication Number Publication Date
ATE316787T1 true ATE316787T1 (de) 2006-02-15

Family

ID=25646491

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01988586T ATE316787T1 (de) 2000-10-26 2001-10-23 Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion

Country Status (29)

Country Link
US (1) US7410983B2 (de)
EP (1) EP1328266B1 (de)
JP (1) JP4236464B2 (de)
KR (1) KR100862129B1 (de)
CN (1) CN1220488C (de)
AR (1) AR035071A1 (de)
AT (1) ATE316787T1 (de)
AU (1) AU2176502A (de)
BG (1) BG65979B1 (de)
BR (1) BR0114701A (de)
CA (1) CA2426625C (de)
CY (1) CY1105007T1 (de)
CZ (1) CZ301282B6 (de)
DE (1) DE60117046T2 (de)
DK (1) DK1328266T3 (de)
DZ (1) DZ3442A1 (de)
EE (1) EE05281B1 (de)
ES (1) ES2257457T3 (de)
HU (1) HUP0303566A3 (de)
IL (2) IL155524A0 (de)
MA (1) MA25847A1 (de)
MX (1) MXPA03003733A (de)
NO (1) NO332260B1 (de)
PL (1) PL212952B1 (de)
PT (1) PT1328266E (de)
RU (1) RU2003111175A (de)
SK (1) SK287992B6 (de)
TN (1) TNSN01151A1 (de)
WO (1) WO2002034259A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284887T3 (es) 2001-07-11 2007-11-16 Boehringer Ingelheim Pharmaceuticals Inc. Metodos para tratar enfermedades transmitidas por citocinas.
CA2481371A1 (en) * 2002-03-11 2003-09-18 Peter Zahradka Use of ppar alpha agonists for the treatment of vascular and renal diseases
US20070225614A1 (en) 2004-05-26 2007-09-27 Endothelix, Inc. Method and apparatus for determining vascular health conditions
FR2845602B1 (fr) * 2002-10-11 2005-07-08 Servier Lab Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
FR2868313B1 (fr) * 2004-03-31 2008-08-15 Servier Lab Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
EP1621200A1 (de) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Pharmazeutische Kombinationen enthaltend einen Hemmstoff der Plättchenaggregation und ein Fibrat
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
JP2009508867A (ja) 2005-09-15 2009-03-05 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体
EP1785133A1 (de) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Verwendung von Fenofibrate oder dessen Derivaten zur Prävention von diabetischer retinopathie
EP1986636B1 (de) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol- und 1,4-benzochinon-derivate zur verwendung in der behandlung von erkrankungen der mitochondrien
US7897326B2 (en) 2006-03-16 2011-03-01 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Peroxisome-proliferator activated receptor-alpha agonists for organ preservation
US20070225606A1 (en) * 2006-03-22 2007-09-27 Endothelix, Inc. Method and apparatus for comprehensive assessment of vascular health
US20080027330A1 (en) * 2006-05-15 2008-01-31 Endothelix, Inc. Risk assessment method for acute cardiovascular events
US20080081963A1 (en) * 2006-09-29 2008-04-03 Endothelix, Inc. Methods and Apparatus for Profiling Cardiovascular Vulnerability to Mental Stress
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
EP2344142B1 (de) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Behandlung von pervasiven entwicklungsstörungen mit redox-aktiven therapeutika
EP2391219A4 (de) * 2009-01-29 2013-03-06 Joshua D Levine Verfahren zum hinzufügen von pflanzlichen stoffen/nahrungsegänzungen zur pharmazeutika bei einer pharmakotherapeutischen behandlung
US8973851B2 (en) 2009-07-01 2015-03-10 The Procter & Gamble Company Apparatus and methods for producing charged fluid droplets
EP2551255B1 (de) * 2010-03-26 2017-11-08 Vivacell Biotechnology España, S.L Cannabinoid quinon-derivate
RU2554500C2 (ru) * 2013-09-20 2015-06-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ лечения ишемического инсульта
EP3389646A1 (de) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouralkyl, flouralkoxy, phenoxy, heteroaryloxy, alkoxy und amin-1,4-benzochinon-derivate zur behandlung von oxidativen stresserkrankungen
US10881686B2 (en) 2017-10-27 2021-01-05 Zeta Biolongevity, Inc Compositions and methods for treating and preventing proteinuria and endothelial erosion
CN110907407B (zh) * 2019-12-03 2022-02-25 东北石油大学 一种基于spr的高灵敏度光子准晶体光纤折射率传感器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229385A (en) * 1986-01-30 1993-07-20 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FI102273B (fi) 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
AU6126098A (en) * 1997-11-28 1999-06-16 Nikolai Vasilievich Karsanov Anti-hypoxic and anti-ischemic drug
US6423742B1 (en) * 1999-09-02 2002-07-23 Drake Larson Compositions for reducing vascular plaque formation and methods of using same

Also Published As

Publication number Publication date
DE60117046D1 (de) 2006-04-13
CN1220488C (zh) 2005-09-28
DE60117046T2 (de) 2006-09-28
BG65979B1 (bg) 2010-08-31
EP1328266B1 (de) 2006-02-01
HK1057340A1 (en) 2004-04-02
MXPA03003733A (es) 2004-10-15
RU2003111175A (ru) 2004-09-10
SK5082003A3 (en) 2003-11-04
CN1471390A (zh) 2004-01-28
IL155524A (en) 2008-08-07
KR20030055276A (ko) 2003-07-02
EE200300165A (et) 2003-06-16
JP2004512302A (ja) 2004-04-22
SK287992B6 (sk) 2012-09-03
EE05281B1 (et) 2010-04-15
US20040022778A1 (en) 2004-02-05
EP1328266A1 (de) 2003-07-23
KR100862129B1 (ko) 2008-10-09
AR035071A1 (es) 2004-04-14
US7410983B2 (en) 2008-08-12
HUP0303566A2 (hu) 2004-03-01
JP4236464B2 (ja) 2009-03-11
PT1328266E (pt) 2006-05-31
PL361635A1 (en) 2004-10-04
CA2426625C (en) 2010-06-01
AU2176502A (en) 2002-05-06
DK1328266T3 (da) 2006-06-06
MA25847A1 (fr) 2003-07-01
CY1105007T1 (el) 2009-11-04
NO20031851D0 (no) 2003-04-24
TNSN01151A1 (en) 2005-11-10
HUP0303566A3 (en) 2005-05-30
DZ3442A1 (fr) 2002-05-02
ES2257457T3 (es) 2006-08-01
CA2426625A1 (en) 2002-05-02
WO2002034259A1 (en) 2002-05-02
IL155524A0 (en) 2003-11-23
BG107765A (bg) 2004-02-27
NO20031851L (no) 2003-06-24
BR0114701A (pt) 2003-11-18
CZ301282B6 (cs) 2009-12-30
PL212952B1 (pl) 2012-12-31
NO332260B1 (no) 2012-08-13

Similar Documents

Publication Publication Date Title
DE60117046D1 (de) Kombination von fenofibrat und von coenzym q10 für die behandlung der endotheliaal missfunktion
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
ATE376994T1 (de) Adamantanderivate zur behandlung von entzündlichen, immunologischen und kardiovaskulären erkrankungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE50214540D1 (de) Stanz bei der behandlung von wunden
DE60022916D1 (de) Reboxetin zur Behandlung von peripheren Neuropathien
DE60216275D1 (de) Verwendung von mit azetidinon substituierten derivaten bei der behandlung der alzheimer-krankheit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE385794T1 (de) Benzothiazolderivate zur behandlung von alzheimer und parkinson
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
ATE538096T1 (de) Pyridinon-derivate zur behandlung von arteriosklerose
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
DE60140516D1 (de) Behandlung von fluorkohlenstoff- ausgangsmaterialien
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
DE60103685D1 (de) Behandlung von Poriomania
ATE391507T1 (de) S-methyl-dihydro-ziprasidone für die behandlung von schizophrenie
DE60005685D1 (de) Oxazinocarbazole zur behandlung von cns-erkrankungen
NO20022253L (no) Middel til behandling av hepatitt C

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1328266

Country of ref document: EP